OBJECTIVE: To provide clinicians with an update on the diagnosis of celiac disease (CD) and to make recommendations on the indications to screen for CD in patients presenting with low bone mineral density (BMD) or fragility fractures. QUALITY OF EVIDENCE: A multidisciplinary task force developed clinically relevant questions related to the diagnosis of CD as the basis for a literature search of the MEDLINE, EMBASE, and CENTRAL databases (January 2000 to January 2009) using the key words celiac disease, osteoporosis, osteopenia, low bone mass, and fracture. The existing literature consists of level I and II studies. MAIN MESSAGE: The estimated prevalence of asymptomatic CD is 2% to 3% in individuals with low BMD. Routine screening for CD is not justified in patients with low BMD. However, targeted screening for CD is recommended for patients who have T-scores of -1.0 or less at the spine or hip, or a history of fragility fractures in association with any CD-related symptoms or conditions; family history of CD; or low urinary calcium levels, vitamin D insufficiency, and raised parathyroid hormone levels despite adequate intake of calcium and vitamin D. Celiac disease testing should be performed while the subject is consuming a gluten-containing diet; initial screening should be performed with human recombinant immunoglobulin (Ig) A tissue transglutaminase or other IgA tissue transglutaminase assays, in association with IgA endomysial antibody immunofluorescence. Duodenal biopsy is necessary to confirm the diagnosis of CD. Human leukocyte antigen typing might assist in confirming or ruling out the diagnosis of CD in cases where serology and histology are discordant. Definitive diagnosis is based on clinical, serologic, and histologic features, combined with a positive response to a gluten-free diet. CONCLUSION: Current evidence does not support routine screening for CD in all patients with low BMD. A targeted case-finding approach is appropriate for patients who are at higher risk of CD.
OBJECTIVE: To provide clinicians with an update on the diagnosis of celiac disease (CD) and to make recommendations on the indications to screen for CD in patients presenting with low bone mineral density (BMD) or fragility fractures. QUALITY OF EVIDENCE: A multidisciplinary task force developed clinically relevant questions related to the diagnosis of CD as the basis for a literature search of the MEDLINE, EMBASE, and CENTRAL databases (January 2000 to January 2009) using the key words celiac disease, osteoporosis, osteopenia, low bone mass, and fracture. The existing literature consists of level I and II studies. MAIN MESSAGE: The estimated prevalence of asymptomatic CD is 2% to 3% in individuals with low BMD. Routine screening for CD is not justified in patients with low BMD. However, targeted screening for CD is recommended for patients who have T-scores of -1.0 or less at the spine or hip, or a history of fragility fractures in association with any CD-related symptoms or conditions; family history of CD; or low urinary calcium levels, vitamin D insufficiency, and raised parathyroid hormone levels despite adequate intake of calcium and vitamin D. Celiac disease testing should be performed while the subject is consuming a gluten-containing diet; initial screening should be performed with human recombinant immunoglobulin (Ig) A tissue transglutaminase or other IgA tissue transglutaminase assays, in association with IgA endomysial antibody immunofluorescence. Duodenal biopsy is necessary to confirm the diagnosis of CD. Human leukocyte antigen typing might assist in confirming or ruling out the diagnosis of CD in cases where serology and histology are discordant. Definitive diagnosis is based on clinical, serologic, and histologic features, combined with a positive response to a gluten-free diet. CONCLUSION: Current evidence does not support routine screening for CD in all patients with low BMD. A targeted case-finding approach is appropriate for patients who are at higher risk of CD.
Authors: K Rostami; J Kerckhaert; R Tiemessen; B M von Blomberg; J W Meijer; C J Mulder Journal: Am J Gastroenterol Date: 1999-04 Impact factor: 10.864
Authors: M C Fornari; S Pedreira; S Niveloni; D González; R A Diez; H Vázquez; R Mazure; E Sugai; E Smecuol; L Boerr; E Mauriño; J C Bai Journal: Am J Gastroenterol Date: 1998-03 Impact factor: 10.864
Authors: T Kemppainen; H Kröger; E Janatuinen; I Arnala; V M Kosma; P Pikkarainen; R Julkunen; J Jurvelin; E Alhava; M Uusitupa Journal: Bone Date: 1999-03 Impact factor: 4.398
Authors: C Catassi; I M Rätsch; L Gandolfi; R Pratesi; E Fabiani; R El Asmar; M Frijia; I Bearzi; L Vizzoni Journal: Lancet Date: 1999-08-21 Impact factor: 79.321
Authors: Irma J A de Bruin; Lisanne Vranken; Caroline E Wyers; Robert Y van der Velde; Thera A M Trienekens; Sjoerd Kaarsemaker; Heinrich M J Janzing; Frank L Wolters; Siep Wouda; Piet P M M Geusens; Joop P W van den Bergh Journal: Calcif Tissue Int Date: 2020-07-28 Impact factor: 4.333